POLRMT and cancer: Both ClpP activation or POLRMT inhibition appears to increase glycolytic dependence in cancer cells (become more “Warburg-like”), although it is unclear why shifting cancer cells away from OXPHOS utilization would be therapeutically beneficial given that many cancers are already highly glycolytic [91,92].